Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

10612studies shown

Showing 5,065-5,076 of 10,612

Drug study icon

TerminatedNCT06431256

Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 4 Years to 5 Years

Countries: United States
Sponsor: Ironshore Pharmaceuticals and Development, Inc
Condition: ADHD

Drug study icon

CompletedNCT00318448

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

This study is completed in the United States and in Canada. It focuses on ADHD.

In United States

ADHDDrugFrom 6 Years to 17 Years

Countries: United States, Canada
Sponsor: Sanofi
Condition: ADHD

Drug study icon

CompletedNCT01567527

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

This summary needs review. Please check the official study record and contact the research team for details.

In United States

BipolarityDrugFrom 18 Years to 65 Years

Countries: United States, Canada, Japan, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Bipolarity

Drug study icon

TerminatedNCT03896945

Efficacy, Safety, and Tolerability of AVP-786 for Negative Symptoms of Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 60 Years

Countries: United States, Bulgaria, Poland
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT02477670

Efficacy, Safety, and Tolerability of AVP-786 for Residual Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 60 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT01668797

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States, Colombia, Malaysia, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT05624268

Efficacy, Safety, and Tolerability of COMP360 in people with TRD

This study is completed in the United States. It focuses on Depression.

In United States

DepressionDrugOver 18 Years

Countries: United States
Sponsor: COMPASS Pathways
Condition: Depression

Drug study icon

CompletedNCT00922272

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 18 Years to 55 Years

Countries: United States
Sponsor: Shire
Condition: Schizophrenia

Drug study icon

CompletedNCT01488929

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

This study is completed in the United States, in Hungary, in Romania, .... It focuses on schizophrenia.

In United States

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States, Hungary, Romania, ...
Sponsor: Targacept Inc.
Condition: Schizophrenia

Drug study icon

CompletedNCT01124708

Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

This summary needs review. Please check the official study record and contact the research team for details.

In United States

ADHDDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Targacept Inc.
Condition: ADHD

Drug study icon

Active Not RecruitingNCT05711940

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in people with TRD

This study is active but not recruiting in the United States, in France, in Canada, .... It focuses on Depression.

In United States

DepressionDrugOver 18 Years

Countries: United States, France, Canada, ...
Sponsor: COMPASS Pathways
Condition: Depression

Drug study icon

CompletedNCT02153502

AVP-786 for depression

This study is completed in the United States. It is testing AVP-786 for depression.

In United States

DepressionDrugOver 18 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Depression

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.